GlassScriptPhysician profile
Barbara J Ellington
NPI 1962524090
$3,940.30
in general payments reported to CMS, 2019-2025
15 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $148 · 2021: $403 · 2022: $695 · 2023: $843 · 2024: $430 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,025.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $554.04 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $521.66 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $508.98 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $288.36 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $272.36 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $201.54 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $188.64 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $145.46 | 2023-2025 | Auvelity |
| Alkermes, INC. | $86.31 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $70.14 | 2019-2025 | Fanapt |
| Braeburn INC. | $27.12 | 2023 | Brixadi |
| Abbvie INC. | $22.21 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.12 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Ellington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.